Strategic partnerships Mogrify has a track record of collaborating with industry leaders such as Astellas Pharma and Parkwalk Advisors, along with continued interest from university-backed funds. A BD opportunity exists in co-development and strategic research partnerships to advance in vivo reprogramming therapies and platform applications.

Regenerative focus The company targets a regenerative medicine market projected to reach $150B by 2028 with in vivo reprogramming therapies in ophthalmology, otology, metabolic diseases, and degenerative conditions. This signals multiple high-value segments for collaboration, licensing, or joint development deals.

Early-stage scalability With a small team and recent Series A funding topping $46M, Mogrify is in pre-clinical translation and optimization phase. There is appetite for tools, services, or co-development programs that accelerate pre-clinical pipelines and regulatory readiness.

Technology leverage Mogrify’s proprietary platforms MOGRIFY and epiMOGRIFY use big-data, sequencing, and regulatory/epigenetic networks to predict factors for target cell generation. This offers opportunities to provide data analytics, bioinformatics services, or platform licensing to pharma and biotech partners.

Leadership and credibility Key hires and advisory appointments (Chief Scientific Officer and Non-Executive Director) alongside high-profile investors enhance credibility for collaboration, funding avenues, and technology licensing discussions with larger biopharma players seeking innovative regenerative solutions.